Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

950 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
Scheen AJ. Scheen AJ. Circ Res. 2018 May 11;122(10):1439-1459. doi: 10.1161/CIRCRESAHA.117.311588. Circ Res. 2018. PMID: 29748368 Free PMC article. Review.
Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine.
Scheen AJ, Paolisso G, Salvatore T, Lefèbvre PJ. Scheen AJ, et al. Diabetes Care. 1991 Apr;14(4):325-32. doi: 10.2337/diacare.14.4.325. Diabetes Care. 1991. PMID: 2060435 Clinical Trial.
Antihyperglycaemic agents. Drug interactions of clinical importance.
Scheen AJ, Lefèbvre PJ. Scheen AJ, et al. Drug Saf. 1995 Jan;12(1):32-45. doi: 10.2165/00002018-199512010-00003. Drug Saf. 1995. PMID: 7741982 Review.
Oral antidiabetic agents. A guide to selection.
Scheen AJ, Lefèbvre PJ. Scheen AJ, et al. Drugs. 1998 Feb;55(2):225-36. doi: 10.2165/00003495-199855020-00004. Drugs. 1998. PMID: 9506242 Review.
The roles of time of day and sleep quality in modulating glucose regulation: clinical implications.
Scheen AJ, Van Cauter E. Scheen AJ, et al. Horm Res. 1998;49(3-4):191-201. doi: 10.1159/000023170. Horm Res. 1998. PMID: 9550124 Review.
The postprandial state and risk of cardiovascular disease.
Lefèbvre PJ, Scheen AJ. Lefèbvre PJ, et al. Among authors: scheen aj. Diabet Med. 1998;15 Suppl 4:S63-8. doi: 10.1002/(sici)1096-9136(1998120);2-z. Diabet Med. 1998. PMID: 9868996 Review.
Glucose metabolism and the postprandial state.
Lefèbvre PJ, Scheen AJ. Lefèbvre PJ, et al. Among authors: scheen aj. Eur J Clin Invest. 1999 Jun;29 Suppl 2:1-6. doi: 10.1046/j.1365-2362.1999.00003.x. Eur J Clin Invest. 1999. PMID: 10383603 Review.
Antiobesity pharmacotherapy in the management of type 2 diabetes.
Scheen AJ, Lefèbvre PJ. Scheen AJ, et al. Diabetes Metab Res Rev. 2000 Mar-Apr;16(2):114-24. doi: 10.1002/(sici)1520-7560(200003/04)16:2<114::aid-dmrr97>;2-o. Diabetes Metab Res Rev. 2000. PMID: 10751751 Review.
Hepatic insulin resistance in obese non-diabetic subjects and in type 2 diabetic patients.
Paquot N, Scheen AJ, Dirlewanger M, Lefèbvre PJ, Tappy L. Paquot N, et al. Among authors: scheen aj. Obes Res. 2002 Mar;10(3):129-34. doi: 10.1038/oby.2002.21. Obes Res. 2002. PMID: 11886934
New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
Scheen AJ, Ernest P. Scheen AJ, et al. Diabetes Metab. 2002 Dec;28(6 Pt 1):437-45. Diabetes Metab. 2002. PMID: 12522323 Review.
950 results
Jump to page